Key result
Lipopolysaccharide pre-treatment significantly reduced myocardial infarct size following ischaemia/reperfusion compared with no treatment (9.3% vs. 32.3%, P<0.01).
Absolute Event Rate: 9.3% vs 32.3%
p-value: p=<0.01
LPS-induced cardioprotection against ischaemia/reperfusion injury in mice is mediated through a PI3K/Akt-dependent mechanism.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for LPS preconditioning in ischaemia/reperfusion; human studies needed before clinical translation.
Ha et al. (2008) studied Ischaemia/reperfusion injury. Lipopolysaccharide (LPS) pre-treatment vs. Untreated group was evaluated on Infarct size (p=<0.01). Lipopolysaccharide pre-treatment significantly reduced myocardial infarct size following ischaemia/reperfusion compared with no treatment (9.3% vs. 32.3%, P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: